Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Guy Griebel

Showing results (61-70 of 68) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 68 results.
Scientific Reports|October 14, 2016
The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophreniaGuy Griebel, Philippe Pichat, Denis Boulay, et al.
Psychopharmacology|December 25, 2010
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsMark D Black, Rachel J Stevens, Nancy Rogacki, et al.
Pharmacology, Biochemistry, and Behavior|May 1, 2012
SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodentsGuy Griebel, Philippe Pichat, Marie-Pierre Pruniaux, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterizationDanielle Gully, Michel Geslin, Laurence Serva, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychoticRonan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, et al.
Scientific Reports|January 7, 2015
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodentsGuy Griebel, Philippe Pichat, Sandra Beeské, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 5, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profileBruno Biton, Olivier E Bergis, Frédéric Galli, et al.
Pageof 7

Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Scientific Reports|October 14, 2016
The mGluR2 positive allosteric modulator, SAR218645, improves memory and attention deficits in translational models of cognitive symptoms associated with schizophreniaGuy Griebel, Philippe Pichat, Denis Boulay, et al.
Psychopharmacology|December 25, 2010
AVE1625, a cannabinoid CB1 receptor antagonist, as a co-treatment with antipsychotics for schizophrenia: improvement in cognitive function and reduction of antipsychotic-side effects in rodentsMark D Black, Rachel J Stevens, Nancy Rogacki, et al.
Pharmacology, Biochemistry, and Behavior|May 1, 2012
SAR110894, a potent histamine H₃-receptor antagonist, displays procognitive effects in rodentsGuy Griebel, Philippe Pichat, Marie-Pierre Pruniaux, et al.
The Journal of Pharmacology and Experimental Therapeutics|March 22, 2002
4-(2-Chloro-4-methoxy-5-methylphenyl)-N-[(1S)-2-cyclopropyl-1-(3-fluoro-4-methylphenyl)ethyl]5-methyl-N-(2-propynyl)-1,3-thiazol-2-amine hydrochloride (SSR125543A): a potent and selective corticotrophin-releasing factor(1) receptor antagonist. I. Biochemical and pharmacological characterizationDanielle Gully, Michel Geslin, Laurence Serva, et al.
Pharmacology, Biochemistry, and Behavior|July 16, 2008
Characterization of SSR103800, a selective inhibitor of the glycine transporter-1 in models predictive of therapeutic activity in schizophreniaDenis Boulay, Philippe Pichat, Gihad Dargazanli, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|June 16, 2005
Neurochemical, electrophysiological and pharmacological profiles of the selective inhibitor of the glycine transporter-1 SSR504734, a potential new type of antipsychoticRonan Depoortère, Gihad Dargazanli, Genevieve Estenne-Bouhtou, et al.
Scientific Reports|January 7, 2015
Selective blockade of the hydrolysis of the endocannabinoid 2-arachidonoylglycerol impairs learning and memory performance while producing antinociceptive activity in rodentsGuy Griebel, Philippe Pichat, Sandra Beeské, et al.
Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology|October 5, 2006
SSR180711, a novel selective alpha7 nicotinic receptor partial agonist: (1) binding and functional profileBruno Biton, Olivier E Bergis, Frédéric Galli, et al.
Pageof 7